JP2020534270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534270A5 JP2020534270A5 JP2020514950A JP2020514950A JP2020534270A5 JP 2020534270 A5 JP2020534270 A5 JP 2020534270A5 JP 2020514950 A JP2020514950 A JP 2020514950A JP 2020514950 A JP2020514950 A JP 2020514950A JP 2020534270 A5 JP2020534270 A5 JP 2020534270A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- sleep
- effective amount
- composition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023008782A JP2023038310A (ja) | 2017-09-14 | 2023-01-24 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
| JP2024091642A JP2024107137A (ja) | 2017-09-14 | 2024-06-05 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558703P | 2017-09-14 | 2017-09-14 | |
| US62/558,703 | 2017-09-14 | ||
| US201862624680P | 2018-01-31 | 2018-01-31 | |
| US201862624678P | 2018-01-31 | 2018-01-31 | |
| US62/624,678 | 2018-01-31 | ||
| US62/624,680 | 2018-01-31 | ||
| US201862653189P | 2018-04-05 | 2018-04-05 | |
| US62/653,189 | 2018-04-05 | ||
| PCT/US2018/051048 WO2019055764A1 (en) | 2017-09-14 | 2018-09-14 | C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023008782A Division JP2023038310A (ja) | 2017-09-14 | 2023-01-24 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020534270A JP2020534270A (ja) | 2020-11-26 |
| JP2020534270A5 true JP2020534270A5 (enExample) | 2021-10-28 |
Family
ID=65723895
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514950A Pending JP2020534270A (ja) | 2017-09-14 | 2018-09-14 | １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| JP2023008782A Pending JP2023038310A (ja) | 2017-09-14 | 2023-01-24 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
| JP2024091642A Pending JP2024107137A (ja) | 2017-09-14 | 2024-06-05 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023008782A Pending JP2023038310A (ja) | 2017-09-14 | 2023-01-24 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
| JP2024091642A Pending JP2024107137A (ja) | 2017-09-14 | 2024-06-05 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220110949A1 (enExample) |
| EP (2) | EP3681510A1 (enExample) |
| JP (3) | JP2020534270A (enExample) |
| AU (2) | AU2018334214A1 (enExample) |
| CA (1) | CA3075872A1 (enExample) |
| IL (2) | IL303083A (enExample) |
| MX (3) | MX2020002889A (enExample) |
| TW (2) | TW202339764A (enExample) |
| WO (1) | WO2019055764A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ773177A (en) | 2012-01-23 | 2022-09-30 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| AU2014256229B2 (en) | 2013-04-17 | 2018-10-04 | Sage Therapeutics, Inc. | 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| NZ791594A (en) | 2016-08-23 | 2025-08-29 | Sage Therapeutics Inc | A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid |
| WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CA3163556A1 (en) * | 2019-12-05 | 2021-06-10 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014256229B2 (en) * | 2013-04-17 | 2018-10-04 | Sage Therapeutics, Inc. | 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| HUE051488T2 (hu) * | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
| NZ791594A (en) * | 2016-08-23 | 2025-08-29 | Sage Therapeutics Inc | A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid |
-
2018
- 2018-09-14 EP EP18786464.0A patent/EP3681510A1/en not_active Withdrawn
- 2018-09-14 US US16/647,203 patent/US20220110949A1/en not_active Abandoned
- 2018-09-14 JP JP2020514950A patent/JP2020534270A/ja active Pending
- 2018-09-14 TW TW111150395A patent/TW202339764A/zh unknown
- 2018-09-14 CA CA3075872A patent/CA3075872A1/en active Pending
- 2018-09-14 TW TW107132510A patent/TW201919642A/zh unknown
- 2018-09-14 IL IL303083A patent/IL303083A/en unknown
- 2018-09-14 AU AU2018334214A patent/AU2018334214A1/en not_active Abandoned
- 2018-09-14 WO PCT/US2018/051048 patent/WO2019055764A1/en not_active Ceased
- 2018-09-14 EP EP23150618.9A patent/EP4218767A1/en active Pending
- 2018-09-14 MX MX2020002889A patent/MX2020002889A/es unknown
-
2020
- 2020-03-08 IL IL273126A patent/IL273126A/en unknown
- 2020-03-13 MX MX2023010064A patent/MX2023010064A/es unknown
- 2020-03-13 MX MX2023010063A patent/MX2023010063A/es unknown
-
2023
- 2023-01-24 JP JP2023008782A patent/JP2023038310A/ja active Pending
- 2023-03-01 US US18/176,571 patent/US20230201224A1/en not_active Abandoned
-
2024
- 2024-06-05 JP JP2024091642A patent/JP2024107137A/ja active Pending
- 2024-08-07 AU AU2024205601A patent/AU2024205601A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534270A5 (enExample) | ||
| JP2022191257A5 (enExample) | ||
| JP2023171776A (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| JP2020528075A5 (enExample) | ||
| JP2014139255A5 (enExample) | ||
| JP2015526458A5 (enExample) | ||
| JP2014528901A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| RU2010142456A (ru) | Синергические комбинации 5'-метилтиоаденозина | |
| JP2021152060A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| JP2016503407A5 (enExample) | ||
| JP2017533220A5 (enExample) | ||
| RU2013127420A (ru) | Способы уменьшения психогенного или компульсивного переедания | |
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2013536837A5 (enExample) | ||
| JPWO2019241442A5 (enExample) | ||
| JP2015522077A5 (enExample) | ||
| RU2014112324A (ru) | Применение органического соединения для лечения синдрома нунан | |
| WO2009003694A3 (en) | Method for treating diseases related to mitochondrial dysfunction | |
| JP2014534229A5 (enExample) | ||
| RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
| JP2017514829A5 (enExample) | ||
| JP2018529747A5 (enExample) |